Lionco Pharmaceutical Group Co.,Ltd.

Shanghai Stock Exchange 603669.SS

Lionco Pharmaceutical Group Co.,Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 20.11

Lionco Pharmaceutical Group Co.,Ltd. Price to Sales Ratio (P/S) is 20.11 on January 14, 2025, a 0.84% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Lionco Pharmaceutical Group Co.,Ltd. 52-week high Price to Sales Ratio (P/S) is 31.06 on December 09, 2024, which is 54.40% above the current Price to Sales Ratio (P/S).
Lionco Pharmaceutical Group Co.,Ltd. 52-week low Price to Sales Ratio (P/S) is 11.82 on February 07, 2024, which is -41.23% below the current Price to Sales Ratio (P/S).
Lionco Pharmaceutical Group Co.,Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 17.53.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 603669.SS

Lionco Pharmaceutical Group Co.,Ltd.

CEO	Ms. Ling Ping Tao
IPO Date	May 28, 2015
Location	China
Headquarters	Commercial and Residential Building 2
Employees	475
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.

Key trends

Past 5 years